Orogen Royalties Inc

Orogen Royalties Inc logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
10K
Market Cap
-
Website
http://www.organon.com
Introduction

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials
Related News

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)

First Posted Date
2008-06-20
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
268
Registration Number
NCT00702234

A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)

First Posted Date
2008-06-20
Last Posted Date
2022-02-02
Lead Sponsor
Organon and Co
Target Recruit Count
50
Registration Number
NCT00702351

Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)

First Posted Date
2008-06-20
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
102
Registration Number
NCT00702546

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)

First Posted Date
2008-06-20
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
15
Registration Number
NCT00702520

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)

First Posted Date
2008-06-20
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
113
Registration Number
NCT00702624

Pregnancy & Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 (Study 38827)(P06056)(COMPLETED)

Completed
Conditions
Pregnancy
Neonates
Interventions
Drug: Org 36286
Drug: recFSH
First Posted Date
2008-06-20
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
44
Registration Number
NCT00702988

A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: montelukast
Drug: placebo (unspecified)
First Posted Date
2008-06-19
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
500
Registration Number
NCT00700661

Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

First Posted Date
2008-06-13
Last Posted Date
2024-06-18
Lead Sponsor
Organon and Co
Target Recruit Count
682
Registration Number
NCT00696878

A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)

First Posted Date
2008-06-13
Last Posted Date
2024-06-20
Lead Sponsor
Organon and Co
Target Recruit Count
1509
Registration Number
NCT00696800

A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)

First Posted Date
2008-06-13
Last Posted Date
2024-06-17
Lead Sponsor
Organon and Co
Target Recruit Count
8
Registration Number
NCT00697255
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy